Published in J Biomed Res on December 01, 2012
Lipoprotein metabolism, dyslipidemia, and nonalcoholic fatty liver disease. Semin Liver Dis (2013) 1.05
Pathogenesis and therapeutic approaches for non-alcoholic fatty liver disease. World J Hepatol (2014) 0.94
S-Adenosylmethionine increases circulating very-low density lipoprotein clearance in non-alcoholic fatty liver disease. J Hepatol (2014) 0.88
Genome-based nutrition: an intervention strategy for the prevention and treatment of obesity and nonalcoholic steatohepatitis. World J Gastroenterol (2015) 0.81
Low LDL-C and high HDL-C levels are associated with elevated serum transaminases amongst adults in the United States: a cross-sectional study. PLoS One (2014) 0.79
Recent insights into farnesoid X receptor in non-alcoholic fatty liver disease. World J Gastroenterol (2014) 0.77
Steatohepatitis and liver fibrosis are predicted by the characteristics of very low density lipoprotein in nonalcoholic fatty liver disease. Liver Int (2016) 0.77
Global Inactivation of the Pla2g6 Gene in Mice Does Not Cause Dyslipidemia under Chow or High-fat Diet Conditions. J Cancer Prev (2013) 0.75
Miltefosine Suppresses Hepatic Steatosis by Activating AMPK Signal Pathway. PLoS One (2016) 0.75
Genetic Determinants of Circulating Lipoproteins in Nonalcoholic Fatty Liver Disease. J Clin Gastroenterol (2017) 0.75
Nonalcoholic fatty liver disease. N Engl J Med (2002) 22.41
Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology (2004) 18.86
The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology (2005) 15.74
Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science (1988) 13.54
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med (2010) 13.33
Weight-reducing effects of the plasma protein encoded by the obese gene. Science (1995) 13.05
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med (2006) 10.97
Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest (2005) 9.09
An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing. Science (2001) 8.73
Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc (1980) 8.36
Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology (2010) 8.05
A novel form of tissue-specific RNA processing produces apolipoprotein-B48 in intestine. Cell (1987) 7.25
Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology (2005) 7.03
Cholesterol and bile acid metabolism are impaired in mice lacking the nuclear oxysterol receptor LXR alpha. Cell (1998) 6.70
Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease. N Engl J Med (2010) 6.45
Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology (1999) 5.75
Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet (2010) 5.31
Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology (2005) 5.11
Apolipoprotein B-48 is the product of a messenger RNA with an organ-specific in-frame stop codon. Science (1987) 4.98
Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the United States. Gastroenterology (2003) 4.95
Insulin resistance and diabetes mellitus in transgenic mice expressing nuclear SREBP-1c in adipose tissue: model for congenital generalized lipodystrophy. Genes Dev (1998) 4.86
Cholesterol and mortality. 30 years of follow-up from the Framingham study. JAMA (1987) 4.05
The severity of ultrasonographic findings in nonalcoholic fatty liver disease reflects the metabolic syndrome and visceral fat accumulation. Am J Gastroenterol (2007) 4.01
PPAR gamma and human metabolic disease. J Clin Invest (2006) 3.83
Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. N Engl J Med (2007) 3.70
Liver X receptor signaling pathways in cardiovascular disease. Mol Endocrinol (2003) 3.59
Regulation of plasma cholesterol by lipoprotein receptors. Science (1981) 3.36
Lipoprotein lipase: from gene to obesity. Am J Physiol Endocrinol Metab (2009) 3.29
LXRS and FXR: the yin and yang of cholesterol and fat metabolism. Annu Rev Physiol (2006) 3.11
Ethnic differences in hepatic steatosis: an insulin resistance paradox? Hepatology (2009) 3.08
Overproduction of large VLDL particles is driven by increased liver fat content in man. Diabetologia (2006) 2.88
Microsomal triglyceride transfer protein and its role in apoB-lipoprotein assembly. J Lipid Res (2003) 2.88
Epidemiology of non-alcoholic fatty liver disease in China. J Hepatol (2008) 2.72
Adipose tissue as a buffer for daily lipid flux. Diabetologia (2002) 2.65
Inhibition of apolipoprotein B100 secretion by lipid-induced hepatic endoplasmic reticulum stress in rodents. J Clin Invest (2008) 2.58
Complexity in the secretory pathway: the assembly and secretion of apolipoprotein B-containing lipoproteins. J Biol Chem (2002) 2.48
Apolipoprotein E: from atherosclerosis to Alzheimer's disease and beyond. Curr Opin Lipidol (1999) 2.48
The novel apolipoprotein A5 is present in human serum, is associated with VLDL, HDL, and chylomicrons, and circulates at very low concentrations compared with other apolipoproteins. Clin Chem (2004) 2.46
Hepatic fatty acid transporter Cd36 is a common target of LXR, PXR, and PPARgamma in promoting steatosis. Gastroenterology (2007) 2.43
Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance. J Hepatol (2009) 2.43
Regulation of plasma triglycerides in insulin resistance and diabetes. Arch Med Res (2005) 2.31
Alterations in adipose tissue and hepatic lipid kinetics in obese men and women with nonalcoholic fatty liver disease. Gastroenterology (2007) 2.29
Clinical review#: Lipodystrophies: genetic and acquired body fat disorders. J Clin Endocrinol Metab (2011) 2.27
Absence of microsomal triglyceride transfer protein in individuals with abetalipoproteinemia. Science (1992) 2.24
High-density lipoprotein heterogeneity and function in reverse cholesterol transport. Curr Opin Lipidol (2010) 2.23
Complete protein sequence and identification of structural domains of human apolipoprotein B. Nature (1986) 2.12
Dissociation between APOC3 variants, hepatic triglyceride content and insulin resistance. Hepatology (2010) 2.09
Common genetic variation in the promoter of the human apo CIII gene abolishes regulation by insulin and may contribute to hypertriglyceridemia. J Clin Invest (1995) 2.05
Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets. Circulation (2007) 2.04
Apolipoprotein synthesis in nonalcoholic steatohepatitis. Hepatology (2002) 2.04
Relations between carotid artery wall thickness and liver histology in subjects with nonalcoholic fatty liver disease. Diabetes Care (2006) 2.04
Transcriptional activation of apolipoprotein CIII expression by glucose may contribute to diabetic dyslipidemia. Arterioscler Thromb Vasc Biol (2010) 2.03
Proposed nomenclature of apoE isoproteins, apoE genotypes, and phenotypes. J Lipid Res (1982) 2.01
Leptin in human physiology and pathophysiology. Am J Physiol Endocrinol Metab (2011) 1.99
Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI. Evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo. J Clin Invest (1986) 1.96
Serum proteomics and biomarker discovery across the spectrum of nonalcoholic fatty liver disease. Hepatology (2010) 1.91
FXR, a multipurpose nuclear receptor. Trends Biochem Sci (2006) 1.85
Type III hyperlipoproteinemia associated with apolipoprotein E deficiency. Science (1981) 1.84
Apolipoprotein E polymorphism in health and disease. Am Heart J (1987) 1.84
An apolipoprotein CIII haplotype protective against hypertriglyceridemia is specified by promoter and 3' untranslated region polymorphisms. Proc Natl Acad Sci U S A (1993) 1.83
Crystal structure of C-terminal truncated apolipoprotein A-I reveals the assembly of high density lipoprotein (HDL) by dimerization. J Biol Chem (2011) 1.72
Effect of bariatric surgery on nonalcoholic fatty liver disease: systematic review and meta-analysis. Clin Gastroenterol Hepatol (2008) 1.68
Apolipoprotein E: from lipid transport to neurobiology. Prog Lipid Res (2010) 1.63
Interaction of swine lipoproteins with the low density lipoprotein receptor in human fibroblasts. J Biol Chem (1976) 1.62
Familial hypobetalipoproteinemia: genetics and metabolism. Cell Mol Life Sci (2005) 1.58
Increased very low density lipoprotein (VLDL) secretion, hepatic steatosis, and insulin resistance. Trends Endocrinol Metab (2011) 1.53
APOA5 genetic variants are markers for classic hyperlipoproteinemia phenotypes and hypertriglyceridemia. Nat Clin Pract Cardiovasc Med (2008) 1.52
Fatty liver in familial hypobetalipoproteinemia: roles of the APOB defects, intra-abdominal adipose tissue, and insulin sensitivity. J Lipid Res (2004) 1.50
The complete sequence and structural analysis of human apolipoprotein B-100: relationship between apoB-100 and apoB-48 forms. EMBO J (1986) 1.49
Liver microsomal triglyceride transfer protein is involved in hepatitis C liver steatosis. Gastroenterology (2006) 1.44
The apoB/apoA-I ratio is better than the cholesterol ratios to estimate the balance between plasma proatherogenic and antiatherogenic lipoproteins and to predict coronary risk. Clin Chem Lab Med (2004) 1.43
Nonalcoholic fatty liver in Asia: Firmly entrenched and rapidly gaining ground. J Gastroenterol Hepatol (2011) 1.40
Early diet-induced non-alcoholic steatohepatitis in APOE2 knock-in mice and its prevention by fibrates. J Hepatol (2005) 1.40
The structure of vitellogenin provides a molecular model for the assembly and secretion of atherogenic lipoproteins. J Mol Biol (1999) 1.37
Rationale for leptin-replacement therapy for severe lipodystrophy. Endocr Pract (2010) 1.35
A targeted apolipoprotein B-38.9-producing mutation causes fatty livers in mice due to the reduced ability of apolipoprotein B-38.9 to transport triglycerides. J Biol Chem (2000) 1.33
Molecular basis of exchangeable apolipoprotein function. Biochim Biophys Acta (2000) 1.33
Adenoviral overexpression of apolipoprotein A-V reduces serum levels of triglycerides and cholesterol in mice. Biochem Biophys Res Commun (2002) 1.32
A role of the bile salt receptor FXR in atherosclerosis. Arterioscler Thromb Vasc Biol (2010) 1.30
Insulin resistance and C-reactive protein as independent risk factors for non-alcoholic fatty liver disease in non-obese Asian men. J Gastroenterol Hepatol (2004) 1.28
Dissociation between intrahepatic triglyceride content and insulin resistance in familial hypobetalipoproteinemia. Gastroenterology (2010) 1.27
Insulin dose response analysis of free fatty acid kinetics. Metabolism (2007) 1.26
Molecular diagnosis of hypobetalipoproteinemia: an ENID review. Atherosclerosis (2007) 1.25
Golgi-associated maturation of very low density lipoproteins involves conformational changes in apolipoprotein B, but is not dependent on apolipoprotein E. J Biol Chem (2007) 1.24
Expression of apolipoprotein C-III in McA-RH7777 cells enhances VLDL assembly and secretion under lipid-rich conditions. J Lipid Res (2010) 1.21
Apolipoprotein CIII overexpressing mice are predisposed to diet-induced hepatic steatosis and hepatic insulin resistance. Hepatology (2011) 1.21
Acute fatty liver of pregnancy. N Engl J Med (1985) 1.21
Impaired secretion of very low density lipoprotein-triglycerides by apolipoprotein E- deficient mouse hepatocytes. J Clin Invest (1997) 1.20
Abetalipoproteinemia: two case reports and literature review. Orphanet J Rare Dis (2008) 1.20
Hepatic, cardiovascular, and endocrine outcomes of the histological subphenotypes of nonalcoholic fatty liver disease. Semin Liver Dis (2008) 1.20
Microsomal triglyceride transfer protein (MTP) regulation in HepG2 cells: insulin negatively regulates MTP gene expression. J Lipid Res (1995) 1.20
Polymorphic markers in apolipoprotein C-III gene flanking regions and hypertriglyceridemia. Arterioscler Thromb Vasc Biol (1996) 1.20
Immune response towards lipid peroxidation products as a predictor of progression of non-alcoholic fatty liver disease to advanced fibrosis. Gut (2005) 1.19
Lipid disorders and mutations in the APOB gene. Clin Chem (2004) 1.18
Structure and dynamics of human apolipoprotein CIII. J Biol Chem (2008) 1.18
Familial hypobetalipoproteinemia: a review. J Lipid Res (2003) 1.17
Overexpression and accumulation of apolipoprotein E as a cause of hypertriglyceridemia. J Biol Chem (1998) 1.17
MTP inhibition as a treatment for dyslipidaemias: time to deliver or empty promises? Expert Opin Ther Targets (2007) 1.15
Liver transplantation using fatty livers: always feasible? J Hepatol (2010) 1.15
Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med (2007) 10.00
Purinergic signaling during inflammation. N Engl J Med (2012) 4.08
Coordinated adenine nucleotide phosphohydrolysis and nucleoside signaling in posthypoxic endothelium: role of ectonucleotidases and adenosine A2B receptors. J Exp Med (2003) 3.71
Heart transplantation in baboons using alpha1,3-galactosyltransferase gene-knockout pigs as donors: initial experience. Nat Med (2004) 3.58
CD39 is the dominant Langerhans cell-associated ecto-NTPDase: modulatory roles in inflammation and immune responsiveness. Nat Med (2002) 3.18
Endogenous adenosine produced during hypoxia attenuates neutrophil accumulation: coordination by extracellular nucleotide metabolism. Blood (2004) 2.80
Dysfunctional CD39(POS) regulatory T cells and aberrant control of T-helper type 17 cells in autoimmune hepatitis. Hepatology (2014) 2.29
ATP release from activated neutrophils occurs via connexin 43 and modulates adenosine-dependent endothelial cell function. Circ Res (2006) 2.23
CD39/ectonucleoside triphosphate diphosphohydrolase 1 provides myocardial protection during cardiac ischemia/reperfusion injury. Circulation (2007) 2.09
Lymphotoxin beta receptor-dependent control of lipid homeostasis. Science (2007) 2.06
Coagulopathy in cirrhosis - the role of the platelet in hemostasis. J Hepatol (2013) 2.01
Contribution of E-NTPDase1 (CD39) to renal protection from ischemia-reperfusion injury. FASEB J (2007) 1.84
Stat3 and Gfi-1 transcription factors control Th17 cell immunosuppressive activity via the regulation of ectonucleotidase expression. Immunity (2012) 1.82
Thrombotic microangiopathic glomerulopathy in human decay accelerating factor-transgenic swine-to-baboon kidney xenografts. J Am Soc Nephrol (2005) 1.79
Central role of Sp1-regulated CD39 in hypoxia/ischemia protection. Blood (2008) 1.79
From the Cover: CD39 deletion exacerbates experimental murine colitis and human polymorphisms increase susceptibility to inflammatory bowel disease. Proc Natl Acad Sci U S A (2009) 1.75
The mitochondrial uncoupling protein-2 promotes chemoresistance in cancer cells. Cancer Res (2008) 1.71
CD39/ENTPD1 expression by CD4+Foxp3+ regulatory T cells promotes hepatic metastatic tumor growth in mice. Gastroenterology (2010) 1.69
CD39 and control of cellular immune responses. Purinergic Signal (2007) 1.68
Promotion of liver regeneration by natural killer cells in a murine model is dependent on extracellular adenosine triphosphate phosphohydrolysis. Hepatology (2013) 1.66
Salutary effects of adiponectin on colon cancer: in vivo and in vitro studies in mice. Gut (2012) 1.65
Thromboregulatory manifestations in human CD39 transgenic mice and the implications for thrombotic disease and transplantation. J Clin Invest (2004) 1.61
Sublethal heat treatment promotes epithelial-mesenchymal transition and enhances the malignant potential of hepatocellular carcinoma. Hepatology (2013) 1.59
Cideb, an ER- and lipid droplet-associated protein, mediates VLDL lipidation and maturation by interacting with apolipoprotein B. Cell Metab (2009) 1.57
alpha1,3-Galactosyltransferase gene-knockout pig heart transplantation in baboons with survival approaching 6 months. Transplantation (2005) 1.56
Extracellular UDP enhances P2X-mediated bladder smooth muscle contractility via P2Y(6) activation of the phospholipase C/inositol trisphosphate pathway. FASEB J (2013) 1.51
IL-27 acts on DCs to suppress the T cell response and autoimmunity by inducing expression of the immunoregulatory molecule CD39. Nat Immunol (2013) 1.50
Carbon monoxide orchestrates a protective response through PPARgamma. Immunity (2006) 1.47
Presecretory oxidation, aggregation, and autophagic destruction of apoprotein-B: a pathway for late-stage quality control. Proc Natl Acad Sci U S A (2008) 1.45
Ectonucleotidases as regulators of purinergic signaling in thrombosis, inflammation, and immunity. Adv Pharmacol (2011) 1.45
Recent progress in understanding protein and lipid factors affecting hepatic VLDL assembly and secretion. Nutr Metab (Lond) (2010) 1.43
HGF and SDF-1-mediated mobilization of CD133+ BMSC for hepatic regeneration following extensive liver resection. Liver Int (2013) 1.42
Extracellular nucleotide signaling in adult neural stem cells: synergism with growth factor-mediated cellular proliferation. Development (2006) 1.41
The level and compartmentalization of phosphatidate phosphatase-1 (lipin-1) control the assembly and secretion of hepatic VLDL. J Lipid Res (2008) 1.39
Modulation of endothelial cell migration by extracellular nucleotides: involvement of focal adhesion kinase and phosphatidylinositol 3-kinase-mediated pathways. Thromb Haemost (2005) 1.38
Cloning and characterization of mouse nucleoside triphosphate diphosphohydrolase-8. Biochemistry (2004) 1.36
Thrombotic microangiopathy associated with humoral rejection of cardiac xenografts from alpha1,3-galactosyltransferase gene-knockout pigs in baboons. Am J Pathol (2008) 1.36
The ecto-nucleoside triphosphate diphosphohydrolase NTPDase2/CD39L1 is expressed in a novel functional compartment within the liver. Hepatology (2002) 1.34
Vascular CD39/ENTPD1 directly promotes tumor cell growth by scavenging extracellular adenosine triphosphate. Neoplasia (2011) 1.34
Disordered purinergic signaling inhibits pathological angiogenesis in cd39/Entpd1-null mice. Am J Pathol (2007) 1.32
Expression of the ecto-ATPase NTPDase2 in the germinal zones of the developing and adult rat brain. Eur J Neurosci (2003) 1.31
Ecto-nucleoside triphosphate diphosphohydrolase 1 (E-NTPDase1/CD39) regulates neutrophil chemotaxis by hydrolyzing released ATP to adenosine. J Biol Chem (2008) 1.31
SP1-dependent induction of CD39 facilitates hepatic ischemic preconditioning. J Immunol (2010) 1.31
Beneficial effects of CD39/ecto-nucleoside triphosphate diphosphohydrolase-1 in murine intestinal ischemia-reperfusion injury. Thromb Haemost (2004) 1.31
Natural killer T cell dysfunction in CD39-null mice protects against concanavalin A-induced hepatitis. Hepatology (2008) 1.27
Predictors of endoscopic inflammation in patients with ulcerative colitis in clinical remission. Inflamm Bowel Dis (2013) 1.27
Expression of P2Y nucleotide receptors and ectonucleotidases in quiescent and activated rat hepatic stellate cells. Am J Physiol Gastrointest Liver Physiol (2004) 1.27
Glucocorticoids and cyclic AMP selectively increase hepatic lipin-1 expression, and insulin acts antagonistically. J Lipid Res (2008) 1.25
Ecto-nucleotidases of the CD39/NTPDase family modulate platelet activation and thrombus formation: Potential as therapeutic targets. Blood Cells Mol Dis (2006) 1.24
The role of purinergic signaling in the liver and in transplantation: effects of extracellular nucleotides on hepatic graft vascular injury, rejection and metabolism. Front Biosci (2008) 1.24
Proprotein convertase subtilisin/kexin type 9 interacts with apolipoprotein B and prevents its intracellular degradation, irrespective of the low-density lipoprotein receptor. Arterioscler Thromb Vasc Biol (2012) 1.21
Expression of apolipoprotein C-III in McA-RH7777 cells enhances VLDL assembly and secretion under lipid-rich conditions. J Lipid Res (2010) 1.21
Intracellular assembly of very low density lipoproteins containing apolipoprotein B100 in rat hepatoma McA-RH7777 cells. J Biol Chem (2002) 1.21
Lipidomics era: accomplishments and challenges. Mass Spectrom Rev (2010) 1.20
Upregulation of CD39/NTPDases and P2 receptors in human pancreatic disease. Am J Physiol Gastrointest Liver Physiol (2006) 1.19
Deletion of cd39/entpd1 results in hepatic insulin resistance. Diabetes (2008) 1.18
Purinergic signaling during inflammation. N Engl J Med (2013) 1.17
Clinical lung xenotransplantation--what donor genetic modifications may be necessary? Xenotransplantation (2012) 1.16
Regulated catalysis of extracellular nucleotides by vascular CD39/ENTPD1 is required for liver regeneration. Gastroenterology (2008) 1.15
Functional analysis of the missense APOC3 mutation Ala23Thr associated with human hypotriglyceridemia. J Lipid Res (2010) 1.15
Expression of NTPDase1 and NTPDase2 in murine kidney: relevance to regulation of P2 receptor signaling. Am J Physiol Renal Physiol (2005) 1.14
Association of the ecto-ATPase NTPDase2 with glial cells of the peripheral nervous system. Glia (2004) 1.12
Missense mutations in APOB within the betaalpha1 domain of human APOB-100 result in impaired secretion of ApoB and ApoB-containing lipoproteins in familial hypobetalipoproteinemia. J Biol Chem (2007) 1.12
P2X7 receptor-mediated purinergic signaling promotes liver injury in acetaminophen hepatotoxicity in mice. Am J Physiol Gastrointest Liver Physiol (2012) 1.10
NTPDase1 governs P2X7-dependent functions in murine macrophages. Eur J Immunol (2010) 1.09
CD73-generated extracellular adenosine in chronic lymphocytic leukemia creates local conditions counteracting drug-induced cell death. Blood (2011) 1.09
Deletion of CD39 on natural killer cells attenuates hepatic ischemia/reperfusion injury in mice. Hepatology (2010) 1.09
The ectonucleotidase cd39/ENTPDase1 modulates purinergic-mediated microglial migration. Glia (2008) 1.08
Expression and distribution of ectonucleotidases in mouse urinary bladder. PLoS One (2011) 1.08
Acute vascular rejection of xenografts: roles of natural and elicited xenoreactive antibodies in activation of vascular endothelial cells and induction of procoagulant activity. Transplantation (2004) 1.07
Extracellular nucleotides as negative modulators of immunity. Curr Opin Pharmacol (2009) 1.07
Nonsynonymous mutations within APOB in human familial hypobetalipoproteinemia: evidence for feedback inhibition of lipogenesis and postendoplasmic reticulum degradation of apolipoprotein B. J Biol Chem (2009) 1.07
Possible effects of microbial ecto-nucleoside triphosphate diphosphohydrolases on host-pathogen interactions. Microbiol Mol Biol Rev (2008) 1.07
TLR stimulation initiates a CD39-based autoregulatory mechanism that limits macrophage inflammatory responses. Blood (2013) 1.06
Biological functions of ecto-enzymes in regulating extracellular adenosine levels in neoplastic and inflammatory disease states. J Mol Med (Berl) (2013) 1.06
Impact of CD39 and purinergic signalling on the growth and metastasis of colorectal cancer. Purinergic Signal (2011) 1.06
A novel nontruncating APOB gene mutation, R463W, causes familial hypobetalipoproteinemia. J Biol Chem (2003) 1.05
RanBPM associates with CD39 and modulates ecto-nucleotidase activity. Biochem J (2006) 1.05
P2X7 integrates PI3K/AKT and AMPK-PRAS40-mTOR signaling pathways to mediate tumor cell death. PLoS One (2013) 1.03
Role of the ectonucleotidase NTPDase2 in taste bud function. Proc Natl Acad Sci U S A (2013) 1.03
Heme oxygenase-1-generated biliverdin ameliorates experimental murine colitis. Inflamm Bowel Dis (2005) 1.02
The vascular ectonucleotidase ENTPD1 is a novel renoprotective factor in diabetic nephropathy. Diabetes (2007) 1.02
Pro-cathepsin D interacts with the extracellular domain of the beta chain of LRP1 and promotes LRP1-dependent fibroblast outgrowth. J Cell Sci (2010) 1.02
Transgenic swine: expression of human CD39 protects against myocardial injury. J Mol Cell Cardiol (2012) 1.02
CD39 is incorporated into plasma microparticles where it maintains functional properties and impacts endothelial activation. Br J Haematol (2008) 1.00
Disordered pancreatic inflammatory responses and inhibition of fibrosis in CD39-null mice. Gastroenterology (2007) 1.00
Making sense of regulatory T cell suppressive function. Semin Immunol (2011) 1.00
Localization of low density lipoprotein receptor-related protein 1 to caveolae in 3T3-L1 adipocytes in response to insulin treatment. J Biol Chem (2003) 0.99
Inhibition of interleukin-17 promotes differentiation of CD25⁻ cells into stable T regulatory cells in patients with autoimmune hepatitis. Gastroenterology (2012) 0.99
GalT-KO pigs: is the cup half empty or half full? Transplantation (2007) 0.99
O-linked glycosylation and functional incompatibility of porcine von Willebrand factor for human platelet GPIb receptors. Xenotransplantation (2005) 0.99
The transgenic expression of human CD39 on murine islets inhibits clotting of human blood. Transplantation (2006) 0.98
Transgenic over expression of ectonucleotide triphosphate diphosphohydrolase-1 protects against murine myocardial ischemic injury. J Mol Cell Cardiol (2011) 0.95
The impact of purinergic signaling on renal ischemia-reperfusion injury. Transplantation (2008) 0.95
Cross-regulation of carbon monoxide and the adenosine A2a receptor in macrophages. J Immunol (2007) 0.95
A Regulatory Network Involving β-Catenin, e-Cadherin, PI3k/Akt, and Slug Balances Self-Renewal and Differentiation of Human Pluripotent Stem Cells In Response to Wnt Signaling. Stem Cells (2015) 0.94
Functional expression of the ecto-ATPase NTPDase2 and of nucleotide receptors by neuronal progenitor cells in the adult murine hippocampus. J Neurosci Res (2005) 0.94